May 1, 2014

Specialty Vaccine Company PaxVax Selected to Present at Cavendish Global Health Impact Forum

Redwood City, May 1, 2014 — PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced that company Chief Executive Officer Ken Kelley will present at the Cavendish Global Health Impact Forum taking place at the United Nations Headquarters and Rockefeller University in New York City, May 5-7, 2014.

PaxVax has created a portfolio of clinical-stage products, including its lead cholera vaccine, which is an oral, single-dose, attenuated cholera vaccine currently in Phase 3 clinical trials. The U.S. Food and Drug Administration has granted this vaccine Fast Track designation in response to the lack of an available U.S. vaccine against cholera. PaxVax’s clinical pipeline also consists of a pandemic oral vectored H5N1 influenza vaccine, which recently concluded a successful Phase 1 clinical trial, as well as oral vectored vaccines for HIV and anthrax, both of which are currently in Phase 1 clinical trials in collaboration with the U.S. National Institutes of Health (NIH). The company also has a pipeline of early-stage travelers’ vaccine candidates for dengue, malaria, and rabies.

“PaxVax is a double bottom line company, focusing on financial as well as social returns. We are developing vaccines both for the people living in the developing and developed world where diseases are endemic and vaccines are needed for protection,” said Kelley. “Our specialty vaccines address diseases that currently lack affordable and easy-to-access solutions. For example, our cholera vaccine for travelers will be the only cholera vaccine available in the United States, the only single-dose oral cholera vaccine in the world, and the only cholera vaccine to demonstrate protection within 10 days. In addition, the single dose and rapid onset of protection demonstrated by this vaccine makes it a potentially critical tool for outbreak control in resource-poor settings.”

The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making, and impact investing. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.

“With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence,” said Michael Moffat, Cavendish co-founder and President. “The quality and originality of PaxVax’s portfolio of vaccine candidates well positions the company to greatly reduce infectious disease transmission for travelers as well as the millions of people who live in areas where diseases like cholera and dengue fever, among others, are endemic.”

PaxVax has raised nearly $75 million from investors including Ignition Partners and Blue Haven Initiative. The company is also supported by grants, contracts, and awards from the NIH through the National Institute of Allergy and Infectious Diseases (NIAID), its Division of Acquired Immunodeficiency Syndrome (DAIDS) and its Division of Microbiology and Infectious Diseases (DMID), as well as the Wellcome Trust and the Bill and Melinda Gates Foundation.

About PaxVax

PaxVax is a privately held specialty vaccine company founded in 2007. PaxVax is focused on travelers’ vaccines with an emerging pipeline in biodefense coupled with a social mission to ensure global access to its vaccines. PaxVax’s clinical-stage product portfolio includes its lead product PXVX0200, which is an oral, single-dose cholera vaccine in Phase 3 clinical trials, a pandemic oral vectored H5N1 influenza vaccine that recently concluded a successful Phase 1 clinical trial, as well as an oral vectored vaccine for anthrax, which is currently in Phase 1 clinical trials in collaboration with the U.S. National Institutes of Health. The company’s proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target any viral or bacterial protein antigen. PaxVax’s vaccine candidates are designed to enhance the desired immune response and offer an easier way to manufacture, store, distribute, administer, and deliver vaccines across the globe compared to conventional injectable vaccines. PaxVax is headquartered in Redwood City, California and has research and development laboratories and state-licensed Good Manufacturing Practice (GMP) production facilities in San Diego, California. More information about PaxVax is available at www.PaxVax.com.

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete peer-to-peer knowledge expansion and relationship building environment combined with the innovative resources required to help develop and implement their individual pro-social impact investment grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources which includes Cavendish Impact Forums. A unique gathering of leading family offices Cavendish Impact Forums take place three times each year: in the United States (taking place in New York at the United Nations Headquarters and at Rockefeller University May 5-7, 2014), Europe (London October 2014 in association with SV Life Sciences hosted by Oxford University) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai UAE January 2015). For more information: http://cavendishglobal.com.

Download Press Release
Specialty Vaccine Company PaxVax Selected to Present at Cavendish Global Health Impact Forum